Patents by Inventor William Brusilow

William Brusilow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of methionine sulfoximine to treat diseases caused by an inflammatory cytokine response
    Patent number: 11207284
    Abstract: Methods for treating or preventing an inflammatory response comprising administering a diastereomer or diastereomeric mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or diastereomeric mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: December 28, 2021
    Inventors: William Brusilow, Paolo Bernardi
  • Use Of Methionine Sulfoximine To Treat Diseases Caused By An Inflammatory Cytokine Response
    Publication number: 20170181994
    Abstract: Methods for treating or preventing an inflammatory response comprising administering a diastereomer or diastereomeric mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or diastereomeric mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response.
    Type: Application
    Filed: January 6, 2017
    Publication date: June 29, 2017
    Inventors: William Brusilow, Paolo Bernardi
  • Use of methionine sulfoximine to treat diseases caused by an inflammatory cytokine response
    Patent number: 9561203
    Abstract: Methods for treating or preventing an inflammatory response comprising administering a diastereomer or diastereomeric mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or diastereomeric mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: February 7, 2017
    Inventors: William Brusilow, Paolo Bernardi
  • USE OF METHIONINE SULFOXIMINE TO TREAT DISEASES CAUSED BY AN INFLAMMATORY CYTOKINE RESPONSE
    Publication number: 20160081958
    Abstract: Methods for treating or preventing an inflammatory response comprising administering a diastereomer or diastereomeric mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or diastereomeric mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response.
    Type: Application
    Filed: August 24, 2015
    Publication date: March 24, 2016
    Inventors: William Brusilow, Paolo Bernardi
  • Use of methionine sulfoximine to treat acute liver failure and other diseases caused by an inflammatory cytokine response
    Patent number: 9119821
    Abstract: Methods for treating or preventing an inflammatory response comprising administering a diastereomer or diastereomeric mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or diastereomeric mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: September 1, 2015
    Inventors: William Brusilow, Paolo Bernardi
  • USE OF METHIONINE SULFOXIMINE TO TREAT ACUTE LIVER FAILURE AND OTHER DISEASES CAUSED BY AN INFLAMMATORY CYTOKINE RESPONSE
    Publication number: 20140121277
    Abstract: Methods for treating or preventing an inflammatory response comprising administering an enantiomer or racemic mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or racemic mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response.
    Type: Application
    Filed: September 9, 2013
    Publication date: May 1, 2014
    Inventors: William Brusilow, Paolo Bernardi
  • Use of methionine sulfoximine to treat acute liver failure and other diseases caused by an inflammatory cytokine response
    Patent number: 8530515
    Abstract: Methods for treating or preventing an inflammatory response comprising administering an enantiomer or racemic mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or racemic mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response.
    Type: Grant
    Filed: August 9, 2011
    Date of Patent: September 10, 2013
    Inventors: William Brusilow, Paolo Bernardi
  • Use of methionine sulfoximine to treat acute liver failure and other diseases caused by an inflammatory cytokine response
    Publication number: 20120035264
    Abstract: Methods for treating or preventing an inflammatory response comprising administering an enantiomer or racemic mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or racemic mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response.
    Type: Application
    Filed: August 9, 2011
    Publication date: February 9, 2012
    Inventors: William Brusilow, Paolo Bernardi
  • Decreasing brain neuronal glutamate levels using alpha-keto branched chain amino acids
    Publication number: 20050256196
    Abstract: The present invention relates to the treatment or prevention of glutamatergic toxicity by the administration of effective amounts of branched chain ?-keto acids alone or in combination with other antiglutamate agents such as L-methionine S-sulfoximine, L-ethionine S-sulfoximine, and glufosinate. In particular, the present invention relates to the treatment or prevention of diseases or conditions which are characterized by increased levels of brain neuronal glutamate.
    Type: Application
    Filed: May 17, 2005
    Publication date: November 17, 2005
    Applicant: Odessa Pharma
    Inventor: William Brusilow